(VIANEWS) – SCYNEXIS (SCYX), Catalyst Pharmaceuticals (CPRX), TPG Specialty Lending (TSLX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SCYNEXIS (SCYX)
492.5% sales growth and 64.05% return on equity
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Earnings Per Share
As for profitability, SCYNEXIS has a trailing twelve months EPS of $0.83.
PE Ratio
SCYNEXIS has a trailing twelve months price to earnings ratio of 3.63. Meaning, the purchaser of the share is investing $3.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 64.05%.
Volume
Today’s last reported volume for SCYNEXIS is 331294 which is 4.6% below its average volume of 347295.
2. Catalyst Pharmaceuticals (CPRX)
70.9% sales growth and 37.49% return on equity
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $1.04.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 13.77. Meaning, the purchaser of the share is investing $13.77 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 37.49%.
Volume
Today’s last reported volume for Catalyst Pharmaceuticals is 94925 which is 93.8% below its average volume of 1531320.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 140% and 122.7%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 87.5%, now sitting on 302.95M for the twelve trailing months.
3. TPG Specialty Lending (TSLX)
11.3% sales growth and 13.82% return on equity
Sixth Street Specialty Lending, Inc. (NYSE: TSLX) is a business development company. The fund provides senior secured loans (first-lien, second-lien, and unitranche), unsecured loans, mezzanine debt, and investments in corporate bonds and equity securities and structured products, non-control structured equity, and common equity with a focus on co-investments for organic growth, acquisitions, market or product expansion, restructuring initiatives, recapitalizations, and refinancing. The fund invests in business services, software & technology, healthcare, energy, consumer & retail, manufacturing, industrials, royalty related businesses, education, and specialty finance. It seeks to finance and lending to middle market companies principally located in the United States. The fund invests in companies with enterprise value between $50 million and $1 billion or more and EBITDA between $10 million and $250 million. The transaction size is between $15 million and $350 million. The fund invests across the spectrum of the capital structure and can arrange syndicated transactions of up to $500 million and hold sizeable positions within its credits.
Earnings Per Share
As for profitability, TPG Specialty Lending has a trailing twelve months EPS of $1.49.
PE Ratio
TPG Specialty Lending has a trailing twelve months price to earnings ratio of 13.5. Meaning, the purchaser of the share is investing $13.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.82%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 13, 2023, the estimated forward annual dividend rate is 1.84 and the estimated forward annual dividend yield is 9.15%.
Sales Growth
TPG Specialty Lending’s sales growth is 44.5% for the ongoing quarter and 11.3% for the next.
Moving Average
TPG Specialty Lending’s value is higher than its 50-day moving average of $19.38 and higher than its 200-day moving average of $18.58.
4. Erie Indemnity Company (ERIE)
10.3% sales growth and 24.54% return on equity
Erie Indemnity Company operates as a managing attorney-in-fact for the subscribers at the Erie Insurance Exchange in the United States. The company provides sales, underwriting, policy issuance, and renewal services for the policyholders on behalf of the Erie Insurance Exchange. It also offers sales related services, including agent compensation, and sales and advertising support services; and underwriting services comprise underwriting and policy processing; and other services consist of customer services and administrative support services, as well as information technology services. Erie Indemnity Company was incorporated in 1925 and is based in Erie, Pennsylvania.
Earnings Per Share
As for profitability, Erie Indemnity Company has a trailing twelve months EPS of $6.78.
PE Ratio
Erie Indemnity Company has a trailing twelve months price to earnings ratio of 40.8. Meaning, the purchaser of the share is investing $40.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.54%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jul 4, 2023, the estimated forward annual dividend rate is 4.76 and the estimated forward annual dividend yield is 1.72%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Erie Indemnity Company’s EBITDA is 4.74.
5. Ingredion Incorporated (INGR)
6.7% sales growth and 17.47% return on equity
Ingredion Incorporated, together with its subsidiaries, produces and sells starches and sweeteners for various industries. It operates through four segments: North America; South America; Asia Pacific; and Europe, Middle East, and Africa. The company offers sweetener products comprising glucose syrups, high maltose syrups, high fructose corn syrups, caramel colors, dextrose, polyols, maltodextrins, glucose and syrup solids, as well as food-grade and industrial starches, biomaterials, and nutrition ingredients. It also provides animal feed products; edible corn oil; refined corn oil to packers of cooking oil and to producers of margarine, salad dressings, shortening, mayonnaise, and other foods; and corn gluten feed used as protein feed for chickens, pet food, and aquaculture. The company's products are derived primarily from processing corn and other starch-based materials, such as tapioca, potato, and rice. It serves food, beverage, paper and corrugating products, brewing, pharmaceutical, textile, and personal care industries, as well as animal feed markets. The company was formerly known as Corn Products International, Inc. and changed its name to Ingredion Incorporated in June 2012. Ingredion Incorporated was founded in 1906 and is headquartered in Westchester, Illinois.
Earnings Per Share
As for profitability, Ingredion Incorporated has a trailing twelve months EPS of $8.27.
PE Ratio
Ingredion Incorporated has a trailing twelve months price to earnings ratio of 11.91. Meaning, the purchaser of the share is investing $11.91 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.47%.
Moving Average
Ingredion Incorporated’s value is under its 50-day moving average of $106.45 and below its 200-day moving average of $102.22.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.2%, now sitting on 8.22B for the twelve trailing months.
Sales Growth
Ingredion Incorporated’s sales growth is 5.1% for the ongoing quarter and 6.7% for the next.
